Focus:
Uncategorised
-
3 June 2020
ASCO 2020: The shifting paradigm in drug development: from tissue specific to tumour-agnostic
Clinical ontology development has traditionally targeted cancer-dependent target identification; over the past two decades, a number of therapeutic modalities have been designed to target a vast array of molecular signatures...
-
3 June 2020
Coronavirus company news summary – Gilead receives more emergency use authorisations for remdesivir – BerGenBio doses first participants in the UK’s ACCORD trial
Dutch research and development vaccine institute Intravacc has partnered with US-based biotechnology firm EpiVax to advance a Covid-19 vaccine candidate based on Intravacc’s Outer Membrane Vesicles (OMV) platform. The aim...
-
2 June 2020
Gilead’s remdesivir gets MHRA green light, but only targets a select group of Covid-19 patients
Last week, Gilead's remdesivir received its first positive scientific opinion from the Medicines and Healthcare products Regulatory Agency (MHRA) under the Early Access to Medicines Scheme (EAMS) for use in...
-
2 June 2020
Relief Therapeutics doses patients in Phase IIb/III study for ARDS in Covid-19
Relief Therapeutics and its partner NeuroRx have initiated dosing of its Phase IIb/III trial of RLF-100 for acute respiratory distress syndrome (ARDS) in Covid-19 patients who are on mechanical ventilation....
-
2 June 2020
Coronavirus company new summary – Gilead reports Phase III results for remdesivir – Emergent wins US Government contract for vaccine manufacturing
Gilead Sciences has reported positive top-line data from the Phase III SIMPLE clinical trial of remdesivir in hospitalised patients with moderate Covid-19 pneumonia. According to the results, patients on the...
-
1 June 2020
Chemokine inhibitors in the bullous pemphigoid pipeline may be the safest treatment for refractory patients
Bullous pemphigoid is an autoimmune skin condition characterised by boils, rashes, and blisters, as well as prolonged inflammation and pruritus. The condition is painful, typically occurring in patients with ailments...
-
1 June 2020
Eli Lilly launches world’s first clinical trial of antibody-based drug for Covid-19
Eli Lilly has initiated a Phase I study of an antibody-based drug, LY-CoV555, against Covid-19. This drug candidate was identified and developed as part of Lilly's collaboration with Vancouver-based AbCellera...
-
1 June 2020
Gilead’s remdesivir a candidate for US government stockpiling or bulk buying in private sector
Remdesivir, Gilead Sciences' drug, could be under consideration to be added to the classified US Strategic National Stockpile (SNS), as well as individual states' stockpiles, in the event donated doses...
-
29 May 2020
Anti-TNF therapy could treat patients suffering from Covid-19-related ARDS
A retrospective study in Wuhan, China, observed that 17% of 99 coronavirus pneumonia patients developed acute respiratory distress syndrome (ARDS). Established anti-tumor necrosis factor (TNF) therapies such as Remicade (infliximab)...
-
29 May 2020
CRUK and partners launch trial repurposing camostat in Covid-19
Cancer Research UK (CRUK) has partnered with Latus Therapeutics and the University of Edinburgh to launch a clinical trial of camostat for Covid-19. The trial is to be known as...